Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Daniele, Bruno
MIRAGE, NCT06275919: Regorafenib for Recurrent Grade 2 and 3 Meningioma ( Trial)	Recruiting	2	104	Europe	Regorafenib 40 MG Oral Tablet, Local Standard of Care	Istituto Oncologico Veneto IRCCS, Bayer	Meningioma, Malignant	12/26	03/27
PACER, NCT01801904 / 2010-024490-39: A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer	Active, not recruiting	2	52	Europe	Panitumumab	National Cancer Institute, Naples, Azienda Ospedaliera G. Rummo	Metastatic Colorectal Cancer	12/24	12/24
NCT05630937 / 2020-001002-26: Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy	Completed	1/2	31	Europe, US	NMS-01940153E	Nerviano Medical Sciences	Unresectable Hepatocellular Carcinoma (HCC)	01/24	08/24
NCT06270602: The ONCOCAMP Study	Recruiting	N/A	15000	Europe	Data collection (retrospective), Data collection (prospective)	National Cancer Institute, Naples	Oncology	01/25	07/26